Eisai files eribulin for breast cancer
This article was originally published in Scrip
Executive Summary
Eisai has submitted regulatory applications for approval of its investigational chemotherapy drug eribulin mesylate (E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the US and the EU.